Anti-oestrogenic chemoprevention of breast cancer-the need to progress (Q35082355)

6 August 2017

1 reference

title

Anti-oestrogenic chemoprevention of breast cancer-the need to progress (English)

1 reference

6 August 2017

Trevor J Powles

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

European Journal of Cancer

6 August 2017

published in

1 reference

6 August 2017

volume

39

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

572-579

1 reference

Estrogen and the risk of breast cancer

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Tamoxifen for breast cancer among hysterectomised women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Proportion of breast cancer cases in the United States explained by well-established risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Estimating the population attributable risk for multiple risk factors using case-control data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Risk factors for breast cancer in women with proliferative breast disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Ductal lavage for detection of cellular atypia in women at high risk for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Breast cancer chemoprevention: current challenges and a look toward the future

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Stage of breast cancer in relation to body mass index and bra cup size

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Is there a reduced risk of breast cancer among women with hip fractures?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Role of the insulin-like growth factor family in cancer development and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Body mass index and post-menopausal breast cancer: an age-specific analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

The epidemiology of serum sex hormones in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Anti-oestrogenic prevention of breast cancer--the make or break point

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Can mammographic densities predict effects of tamoxifen on the breast?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Heritability of mammographic density, a risk factor for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Rheumatoid symptoms following breast cancer treatment: a controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Polygenic susceptibility to breast cancer and implications for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Molecular determinants for the tissue specificity of SERMs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

Aromatase and its inhibitors: significance for breast cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900771-2

7 January 2021

10.1016/S0959-8049(02)00771-2

Identifiers

DOI

1 reference

6 August 2017

1 reference